Integra LifeSciences Launches Coral Cobalt Chrome Rods
PLAINSBORO, N.J., Sep 1, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the launch of 5.5mm Coral(TM) cobalt chrome rods in a range of lengths for use in spinal correction and fusion procedures. With the addition of cobalt chrome rods, the Coral(TM) Spinal System now offers three rod options, which also include rigid and malleable titanium rods. Integra will feature the Coral(TM) cobalt chrome rods at the XIV World Congress of Neurological Surgery in Boston, Massachusetts, August 30 - September 3, 2009.
By offering a range of rod options, the surgeon can now make intra-operative decisions on rod rigidity after the placement of spinal screws. The unique properties of cobalt chrome alloy make the new rods stiffer than the titanium rods currently offered in the Coral(TM) Spinal System. The increased stiffness helps maintain spinal correction under heavier loads without compromising imaging capabilities. In addition, cobalt chrome rods have minimal spring back capability, thereby reducing the need to over bend the rods when adjusting them for specific curve correction.
"We are very pleased to add cobalt chrome rods to our Coral(TM) Spinal System, which will give the surgeon broader options when treating the patient," stated Randy Theken, President of Integra Spine.
In 2007, the largest of all three segments in the U.S. spinal fusion market (cervical, interbody and thoracolumbar) was the traditional thoracolumbar implant market, consisting of devices used in thoracolumbar fusions for degenerative, deformity, and trauma/tumor conditions. Valued at over $1.9 billion in 2007, the traditional thoracolumbar implant market is expected to grow steadily. Many thoracolumbar procedures may be performed using a pedicle screw system such as the Coral(TM) Spinal System.
The Coral(TM) cobalt chrome rod is distributed through the Integra Spine independent distributor network. Integra Spine is a leading provider of fusion implants and orthobiologics used in spinal surgery, and is actively developing motion preservation devices. Visit www.integraspine.com for more information.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information visit www.integra-ls.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Coral(TM) Spinal System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
IART-P
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Integra LifeSciences Holdings Corp.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella, Director of Corporate Communications (609) 936-2389 gsabella@integra-LS.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX